Company profile for Xencor

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug fea...
Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
111 West Lemon Avenue Monrovia, CA 91016
Telephone
Telephone
(626) 305-5900
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251110946225/en/Xencor-to-Participate-at-Upcoming-Investor-Conferences

BUSINESS WIRE
10 Nov 2025

https://www.businesswire.com/news/home/20251105353167/en/Xencor-Reports-Third-Quarter-2025-Financial-Results

BUSINESS WIRE
05 Nov 2025

https://www.businesswire.com/news/home/20251024632665/en/Xencor-Presents-Initial-Data-for-XmAb819-a-First-in-class-ENPP3-x-CD3-Bispecific-T-Cell-Engager-in-Development-for-Clear-Cell-Renal-Cell-Carcinoma

BUSINESSWIRE
24 Oct 2025

https://www.businesswire.com/news/home/20251020540696/en/Xencor-to-Host-Webcast-and-Conference-Call-to-Discuss-Initial-Results-from-the-Ongoing-Phase-1-Dose-Escalation-Study-of-XmAb819-in-Advanced-Clear-Cell-Renal-Cell-Carcinoma

BUSINESSWIRE
21 Oct 2025

https://www.businesswire.com/news/home/20251014017914/en/Xencor-Announces-Presentation-of-Initial-Phase-1-Dose-Escalation-Results-of-XmAb819-in-Clear-Cell-Renal-Cell-Carcinoma-at-the-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics

BUSINESSWIRE
14 Oct 2025

https://www.businesswire.com/news/home/20250827152752/en/Xencor-to-Participate-at-Upcoming-Investor-Conferences

BUSINESSWIRE
27 Aug 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty